Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting cancer-specific mutations with RNA-triggered chromatin shredding.

Nature·2026
Same author

Toward a Random Background for Ligand Optimization.

bioRxiv : the preprint server for biology·2026
Same author

Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding.

bioRxiv : the preprint server for biology·2026
Same author

Two decades of PARP inhibitor synthetic lethality in cancer.

Nature·2026
Same author

Comparative sequence analysis of the mouse pseudoautosomal region from three inbred strains reveals it to be the most rapidly evolving 'chromosome'.

Proceedings of the Japan Academy. Series B, Physical and biological sciences·2026
Same author

Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.

British journal of cancer·2026

Related Experiment Video

Updated: Mar 24, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.

James Campbell1, Colm J Ryan2, Rachel Brough1

  • 1The Breast Cancer Now Research Centre and CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK.

Cell Reports
|March 8, 2016
PubMed
Summary

This study identifies kinase genetic dependencies in 117 cancer cell lines using siRNA screens. Integrating this data with molecular profiles reveals cancer vulnerabilities linked to specific driver gene mutations, aiding therapeutic target discovery.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Identification of Kinase-substrate Pairs Using High Throughput Screening
11:13

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

8.7K

Related Experiment Videos

Last Updated: Mar 24, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Identification of Kinase-substrate Pairs Using High Throughput Screening
11:13

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

8.7K

Area of Science:

  • Genomics
  • Cancer Biology
  • Pharmacogenomics

Background:

  • Identifying cancer-specific vulnerabilities is crucial for developing targeted therapies.
  • Genetic dependencies in cancer cell lines offer a platform for discovering these vulnerabilities.

Purpose of the Study:

  • To profile kinase genetic dependencies across diverse cancer cell lines.
  • To integrate genetic dependency data with molecular profiles to identify cancer driver gene-associated vulnerabilities.
  • To demonstrate the utility of this resource for predicting drug sensitivity.

Main Methods:

  • Conducted siRNA screens to identify kinase genetic dependencies in 117 cancer cell lines from ten cancer types.
  • Integrated siRNA screen data with exome sequencing and protein-protein interaction data.
  • Analyzed functional interaction networks to understand gene dependency connections.

Main Results:

  • Identified specific kinase genetic dependencies across various cancer types.
  • Linked genetic dependencies to mutations in cancer driver genes.
  • Demonstrated that dependencies form dense networks with cancer driver genes.
  • Predicted drug sensitivity in specific tumor subsets, including FGFR inhibitor sensitivity in osteosarcoma and mitotic inhibitor sensitivity in SMAD4 mutant cells.

Conclusions:

  • The integrated dataset provides a valuable resource for identifying cancer-specific vulnerabilities and therapeutic targets.
  • Understanding genetic dependencies linked to driver mutations can guide precision medicine approaches.
  • This approach can predict drug responses in genetically defined cancer populations.